(Q34275902)

1 August 2017

1 reference

title

Identifying the patient at risk for post-transplant lymphoproliferative disorder (English)

1 reference

post-transplant lymphoproliferative disorder

1 August 2017

main subject

0 references

1 reference

Cockfield SM

1

1 reference

1 August 2017

publication date

1 June 2001

1 reference

Transplant Infectious Disease

1 August 2017

published in

1 reference

1 August 2017

volume

3

1 reference

1 August 2017

issue

2

1 reference

1 August 2017

page(s)

70-78

1 reference

The Epstein-Barr virus and post-transplant lymphoproliferative disease: interplay of immunosuppression, EBV, and the immune system in disease pathogenesis

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002070.X

7 January 2021

Transfer of a functional human immune system to mice with severe combined immunodeficiency

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002070.X

7 January 2021

Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: the role of primary infection

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002070.X

7 January 2021

Epstein-Barr virus transmission via the donor organs in solid organ transplantation: polymerase chain reaction and restriction fragment length polymorphism analysis of IR2, IR3, and IR4

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002070.X

7 January 2021

Transmission of donor Epstein-Barr virus (EBV) in transplanted organs causes lymphoproliferative disease in EBV-seronegative recipients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002070.X

7 January 2021

Post-transplant lymphoproliferative disorder in renal allograft recipients. Clinical experience and risk factor analysis in a single center

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002070.X

7 January 2021

Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002070.X

7 January 2021

Pretransplantation assessment of the risk of lymphoproliferative disorder

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002070.X

7 January 2021

Epstein-Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppression

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002070.X

7 January 2021

Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002070.X

7 January 2021

Risk of lymphoid neoplasia after cardiothoracic transplantation. a cohort study of the relation to Epstein-Barr virus

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002070.X

7 January 2021

Detection of multiple 'Ebnotypes' in individual Epstein-Barr virus carriers following lymphocyte transformation by virus derived from peripheral blood and oropharynx

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002070.X

7 January 2021

Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity?

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002070.X

7 January 2021

Epstein-Barr virus-negative lymphoproliferate disorders in long-term survivors after heart, kidney, and liver transplant

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002070.X

7 January 2021

Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002070.X

7 January 2021

A low incidence of posttransplant lymphoproliferative disorder in 109 lung transplant recipients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002070.X

7 January 2021

The clinical spectrum, pathology, and clonal analysis of Epstein-Barr virus-associated lymphoproliferative disorders in heart-lung transplant recipients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002070.X

7 January 2021

Intestinal transplantation: 1997 report of the international registry. Intestinal Transplant Registry

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002070.X

7 January 2021

Clinical intestinal transplantation: new perspectives and immunologic considerations

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002070.X

7 January 2021

B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002070.X

7 January 2021

Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002070.X

7 January 2021

Pre-transplant immunological profile and risk factor analysis of post-transplant lymphoproliferative disease development: the results of a nested matched case-control study. The University of Pittsburgh PTLD Study Group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002070.X

7 January 2021

Post-transplant lymphoproliferative disease (PTLD): lymphokine production and PTLD.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002070.X

7 January 2021

Interleukin-6 production in posttransplant lymphoproliferative disease

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002070.X

7 January 2021

Interleukin-10 in Epstein-Barr virus-associated post-transplant lymphomas

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002070.X

7 January 2021

INTERLEUKIN-10 AND POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER AFTER KIDNEY TRANSPLANTATION1

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002070.X

7 January 2021

Cytokine mRNA profiles in Epstein-Barr virus-associated post-transplant lymphoproliferative disorders

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002070.X

7 January 2021

Interleukin-18, interferon-gamma, IP-10, and Mig expression in Epstein-Barr virus-induced infectious mononucleosis and posttransplant lymphoproliferative disease

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002070.X

7 January 2021

Interferon-alpha and its effects on post-transplant lymphoproliferative disorders

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002070.X

7 January 2021

Polymorphism of the interleukin-10 gene is associated with susceptibility to Epstein-Barr virus infection

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002070.X

7 January 2021

Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: the role of cytomegalovirus disease

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002070.X

7 January 2021

Role of hepatitis C virus in lymphoproliferative disorders after liver transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002070.X

7 January 2021

Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002070.X

7 January 2021

Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002070.X

7 January 2021

Conversion from cyclosporine to FK506 for salvage of immunocompromised pediatric liver allografts. Efficacy, toxicity, and dose regimen in 23 children

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002070.X

7 January 2021

Cytomegalovirus infection and posttransplant lymphoproliferative disease in renal transplant recipients: results of the U.S. multicenter FK506 Kidney Transplant Study Group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002070.X

7 January 2021

A BLINDED, LONG-TERM, RANDOMIZED MULTICENTER STUDY OF MYCOPHENOLATE MOFETIL IN CADAVERIC RENAL TRANSPLANTATION

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002070.X

7 January 2021

A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002070.X

7 January 2021

Potential of daclizumab in solid organ transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002070.X

7 January 2021

Post-transplant lymphoproliferative disorders: a preventable complication of solid organ transplantation?

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002070.X

7 January 2021

The management of Epstein-Barr virus associated post-transplant lymphoproliferative disorders in pediatric solid-organ transplant recipients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002070.X

7 January 2021

Quantitative oropharyngeal Epstein-Barr virus shedding in renal and cardiac transplant recipients: relationship to immunosuppressive therapy, serologic responses, and the risk of posttransplant lymphoproliferative disorder

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002070.X

7 January 2021

Epstein-Barr virus in inflammatory diseases of the liver and liver allografts: an in situ hybridization study

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002070.X

7 January 2021

The role of antiviral and immunoglobulin therapy in the prevention of Epstein-Barr virus infection and post-transplant lymphoproliferative disease following solid organ transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002070.X

7 January 2021

Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002070.X

7 January 2021

10.1034/J.1399-3062.2001.003002070.X

Identifiers

DOI

1 reference

1 August 2017

1 reference